Know Cancer

forgot password

IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Plus Capecitabine or Capecitabine Plus Docetaxel in the Treatment of Metastatic Breast Cancer

Phase 2
18 Years
Not Enrolling
Breast Neoplasms

Thank you

Trial Information

IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Plus Capecitabine or Capecitabine Plus Docetaxel in the Treatment of Metastatic Breast Cancer

Inclusion Criteria:

- Participants with metastatic breast cancer

- Measurable disease

- Up to 1 chemotherapy regimen is acceptable. Participants who have received paclitaxel
in the neoadjuvant or adjuvant setting acceptable, only if the last dose of
paclitaxel was received 12 months or less before the treatment. There is no timeframe
for prior paclitaxel in the metastatic setting.

- Human epidermal growth factor receptor 2-positive participants allowed if they have
progressed after receiving treatment with trastuzumab or lapatinib

- Eastern Cooperative Oncology Group Performance status of 0-1

- Age younger than 18 years

- Women of childbearing potential must be using an adequate method of contraception to
avoid pregnancy throughout the study and for at least 4 weeks after the last dose of
investigational products

Exclusion Criteria:

- More than 1 chemotherapy regimen for the treatment of metastatic breast cancer

- Prior treatment with any epothilone, capecitabine, or docetaxel

- Prior radiation must not have included 30% or more of major bone marrow-containing
areas (pelvis, lumbar spine). If prior radiation was less than 30%, a minimum
interval of 2 weeks must be allowed between the last radiation treatment and
administration of study medication. There must be at least 1 week between
focal/palliative radiation and administration of study medication.

- Any current or previous history of brain and/or leptomeningeal metastases

- Neuropathy greater than Grade 2

- Any concurrent malignancy other than nonmelanoma skin cancer or carcinoma in situ of
the cervix

- Uncontrolled diabetes mellitus

- Chronic hepatitis

- HIV-positive status

- Administration of trastuzumab, lapatinib, bevacizumab, or other systemic treatment
for cancer must be discontinued 28 days prior to study medication. Hormonal
anticancer agents must be discontinued at least 14 days prior to study medication.
Hormonal replacement therapy is acceptable

- Biphosphonates for palliation of bone metastases allowed if initiated at least 7 days
before study entry

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Participants With Best Tumor Response as Assessed With Response Evaluation Criteria in Solid Tumors (RECIST)

Outcome Description:

RECIST definitions: Complete reponse (CR)=disappearance of all nontarget lesions; partial response (PR)=at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD; stable disease (SD)=neither PR nor progressive disease (PD) criteria were met; PD=at least 20% increase in the sum of the LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline. Tumor status assessed by investigator.

Outcome Time Frame:

Baseline to 6 weeks (end of Cycle 2)

Safety Issue:


Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb


United States: Food and Drug Administration

Study ID:




Start Date:

February 2008

Completion Date:

March 2010

Related Keywords:

  • Breast Neoplasms
  • Breast Neoplasms
  • Neoplasms



Sinai Hospital of Baltimore Baltimore, Maryland  21225
Mary Bird Perkins Cancer Center Baton Rouge, Louisiana  70809
Akron General Medical Center Akron, Ohio  44302
Albert Einstein Cancer Center Philadelphia, Pennsylvania  19141
Midwestern Regional Medical Center Zion, Illinois  60099
DCH Cancer Treatment Center Tuscaloosa, Alabama  35401
Summa Health System Akron, Ohio  44312
Center for Cancer Care at Goshen Health System Goshen, Indiana  46526
Jackson Oncology Associates, PLLC Jackson, Mississippi  39202
Gaston Hematology and Oncology Gastonia, North Carolina  28054
Doylestown Hospital Doylestown, Pennsylvania  18901
Scripps Cancer Center La Jolla, California  92037
Charleston Cancer Center Charleston, South Carolina  29406
The Center for Cancer and Hematologic Disease Cherry Hill, New Jersey  08003
Local Institution Cincinnati, Ohio  
Georgetown University Medical Center Washington, District of Columbia  20007
University of Kentucky Lexington, Kentucky  40536-0098
Local Institution Fort Lauderdale, Florida  
Local Institution New Brunswick, New Jersey  
Local Institution Duncansville, Pennsylvania  
Cancer Specialists of South Texas Corpus Christi, Texas  78412
Santee Hematology/Oncology Sumter, South Carolina  29150
Northwestern University Feinberg School of Medicine Chicago, Illinois  60611
Peninsula Cancer Institute Newport News, Virginia  23601
Hematology & Oncology Associates of NEPA Dunmore, Pennsylvania  18512
Marion L Shepard Cancer Center Washington, North Carolina  27889
Local Institution Providence, Rhode Island  
The Cancer Center at Hackensack University Medical Center Hackensack, New Jersey  07601
Cancer Center of Kansas Wichita, Kansas  67214
Hematology/Oncology Clinic Baton Rouge, Louisiana  70808
Howell Office Plaza Howell, New Jersey  07731
Coastal Bend Cancer Center Corpus Christi, Texas  78404
Local Institution Honolulu, Hawaii  
Local Institution Newark, Delaware  
Cancer Center of Central Connecticut Southington, Connecticut  
Arena Oncology Associates, PC Great Neck, New York  11021
Lowcountry Hematology & Oncology, Pa Mt. Pleasant, South Carolina  29464
Hematology Oncology Associates of Rockland Nyack, New York  10960
Kingsport Hematology Oncology Kingsport, Tennessee  37660
University Medical Center, Inc Louisville, Kentucky  40202
Providence Cancer Center Spokane, Washington  99204
Monroe Medical Associates Munster, Indiana  46321
Medical Oncology Associates of Augusta, PC Augusta, Georgia  30901
John W Kugler, MD Peoria, Illinois  61615
Center for Cancer & Blood Disorders, PC Bethesda, Maryland  20817
Cooper Hospital, Division of Hematology/Oncology Voorhees, New Jersey  08043
UNM Cancer Center Albuquerque, New Mexico  87106
New Mexico Cancer Care Associates (NMCCA) Santa Fe, New Mexico  87505
Mid Ohio Oncology/Hematology, Inc, dba The Mark H Zangmeister Center Columbus, Ohio  43219
St Mary Medical Center Langhorne, Pennsylvania  19047
Regional Hematology Oncology, PC Langhorne, Pennsylvania  19047
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota  57104
The University of Tennessee Medical Center Knoxville, Tennessee  37920
Austin Cancer Centers Austin, Texas  78759
Edward L Middleman, MD Duncanville, Texas  75137
Section Chief Medical Oncology Houston, Texas  77030
Jose A Figueroa, MD Lubbock, Texas  79410
Southlake Oncology Southlake, Texas  76092
Leah L Dietrich, MD La Crosse, Wisconsin  54601